Dylan MorrisGeneral Partner at CRV
Dylan Morris is a General Partner in CRV’s Bioengineering practice. He serves on the boards of Dyno Therapeutics, Deciduous Therapeutics, and Switch Therapeutics; and has led the firm’s investments in Recursion Pharmaceuticals, Exo Therapeutics, Plexium, and 3T Biosciences. He previously invested at Innovation Endeavors, an early-stage venture firm backed by Eric Schmidt, of Google/Alphabet. At IE, Dylan drove investments in companies operating at the intersection of computing and biology, including Freenome, a CRV portfolio company that applies deep learning to liquid biopsy for early cancer detection. Previously, he cofounded Integrated Plasmonics, a venture-backed point-of-care diagnostics startup. Dylan conducted graduate research in Biophysics at Caltech and received his A.B. in Computer Science from Harvard.